Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease description

Long-term morbidity

3 evidence topics · 2 sources

Cognitive and adaptive functioning

“Intellectual disability was detected in 33/42 (79%) individuals, while 31/35 (89%) demonstrated significant impairments in adaptive functioning.” (opens the source at this quote in a new tab)

Distribution of intellectual outcomes among survivors

“Of 42 subjects whose intellectual abilities were professionally evaluated, 19% had normal or borderline intellectual ability (CQ/IQ ≥ 70), 10% had mild intellectual disability (ID) (CQ/IQ 55–69), 17% had moderate ID (CQ/IQ 40–54), 24% had severe ID (CQ/IQ 25–39) and 33% had profound ID (CQ/IQ < 25).” (opens the source at this quote in a new tab)

“The average outcome for females was severe-to-profound ID, whereas that of males was mild-to-moderate ID.” (opens the source at this quote in a new tab)

“Of 10 subjects who reached age 12 years, 9 had had professional IQ assessments, and only 4 had IQs ≥ 70” (opens the source at this quote in a new tab)

Ambulation and age-appropriate walking

“Although 27/39 (69%) were ambulatory, only 8/39 (21%) demonstrated age‐appropriate walking ability.” (opens the source at this quote in a new tab)